Savita Rangarajan
Overview
Explore the profile of Savita Rangarajan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
2808
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Young G, Kavakli K, Klamroth R, Matsushita T, Peyvandi F, Pipe M.D S, et al.
Blood
. 2025 Mar;
PMID: 40053895
Fitusiran, a subcutaneous investigational siRNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia. This phase 3 open-label extension study (ATLAS‑OLE, NCT03754790) evaluated safety...
2.
Shetty S, Ross C, John M, Kshirsagar S, Kulkarni N, Pavitra D, et al.
Haemophilia
. 2024 Dec;
31(1):132-139.
PMID: 39737851
Introduction: Mortality and morbidity in persons with haemophilia (PWH) have decreased due to improved diagnosis and treatment along with comprehensive population outreach efforts, but the impact is not uniform in...
3.
Quon D, Jackson S, Alvarez-Roman M, Khan U, Casiano S, Ragni M, et al.
Blood Adv
. 2024 Jul;
8(18):4751-4755.
PMID: 39042888
No abstract available.
4.
Symington E, Rangarajan S, Lester W, Madan B, Pierce G, Raheja P, et al.
Haemophilia
. 2024 Jul;
30(5):1138-1147.
PMID: 38975624
Introduction: Valoctocogene roxaparvovec is an adeno-associated virus vector serotype 5 (AAV5)-mediated gene therapy approved for severe haemophilia A (HA). Aim: To report the safety and efficacy of valoctocogene roxaparvovec 7...
5.
Doxzen K, Adair J, Fonseca Bazzo Y, Bukini D, Cornetta K, Dalal V, et al.
Sci Transl Med
. 2024 May;
16(746):eadn1902.
PMID: 38718130
Gene therapies are designed to address the root cause of disease. As scientific understanding of disease prevention, diagnosis, and treatment improves in tandem with technological innovation, gene therapies have the...
6.
Symington E, Rangarajan S, Lester W, Madan B, Pierce G, Raheja P, et al.
Haemophilia
. 2024 Feb;
30(2):320-330.
PMID: 38317480
Introduction: Valoctocogene roxaparvovec uses an adeno-associated virus serotype 5 (AAV5) vector to transfer a factor VIII (FVIII) coding sequence to individuals with severe haemophilia A, providing bleeding protection. Aim: To...
7.
Choraria N, Rangarajan S, John M, Apte S, Gupta P, Pai S, et al.
Indian J Hematol Blood Transfus
. 2023 Oct;
39(4):630-634.
PMID: 37790744
Purpose: Hemophilia B is an X-linked congenital bleeding disorder caused by a deficiency of coagulation factor IX (FIX) clotting activity. This study evaluated safety and efficacy of nonacog alfa, a...
8.
Cornetta K, Kay S, Urio F, Minja I, Mbugi E, Mgaya J, et al.
Mol Ther
. 2023 Aug;
31(9):2561-2565.
PMID: 37595584
There has been rapid growth in gene therapy development with an expanding list of approved clinical products. Several therapies are particularly relevant to patients in low- and middle-income countries. Moreover,...
9.
Boyce S, Rangarajan S
J Blood Med
. 2023 May;
14:317-327.
PMID: 37123985
Severe hemophilia is associated with spontaneous, prolonged and recurrent bleeding. Inadequate prevention and treatment of bleeding can lead to serious morbidity and mortality. Due to the limitations of intravenous clotting...
10.
Bansal S, Donners A, Fischer K, Kshirsagar S, Rangarajan S, Phadke V, et al.
Haemophilia
. 2023 Apr;
29(3):931-934.
PMID: 37029771
No abstract available.